Pregnancy SmartSiteTM

Skip Navigation Schedule An Appointment

Normal Pregnancy

Alcohol and pregnancy Managing your weight gain in pregnancy Steps to take before you get pregnant When you need to gain more weight during pregnancy Aches and pains during pregnancy Choosing the right practitioner Common symptoms during pregnancy Hyperemesis Gravidarum Morning sickness Pregnancy and travel Pregnancy and work Problems sleeping during pregnancy Skin and hair changes during pregnancy Teenage pregnancy Cribs and crib safety Eat right during pregnancy Preparing your other children Amniocentesis Chorionic villus sampling Genetic counseling before pregnancy Glucose tolerance test-pregnancy Monitoring your baby before labor Nuchal translucency Prenatal care in your first trimester Prenatal care in your second trimester Prenatal care in your third trimester

MIBG scintiscan

An MIBG scintiscan is a type of imaging test. It uses a radioactive substance (called a tracer). A scanner finds or confirms the presence of and . These are types of tumors that affect nerve tissue.

A radioisotope (MIBG, iodine-131-meta-iodobenzylguanidine, or iodine-123-meta-iodobenzylguanidine) is injected into a vein. This compound attaches to specific tumor cells.

You will have the scan later that day or the next day. For this part of the test, you lie on a table under the arm of the scanner. Your abdomen is scanned. You may need to return for repeated scans for 1 to 3 days. Each scan takes 1 to 2 hours.

Before or during the test, you may be given an iodine mixture. This prevents your thyroid gland from absorbing too much of the radioisotope.

You will need to sign an informed consent form. You will be asked to wear a hospital gown or loose-fitting clothes. You will need to remove jewelry or metal objects before each scan. Many drugs interfere with the test. Ask your health care provider which of your regular medicines you may need to stop taking before the test.

You will feel a sharp needle prick when the material is injected. The table may be cold or hard. You must lie still during the scan.

This test is done to help diagnose pheochromocytoma. It is done when an  or an  does not give a definite answer. It is also used to help diagnose neuroblastoma and can be used for carcinoid tumors.

There are no signs of a tumor.

Abnormal results may indicate:

  • Carcinoid tumor
  • Neuroblastoma
  • There is some exposure to radiation from the radioisotope. The radiation from this radioisotope is higher than from many others. You may need to take extra precautions for a few days after the test. Your provider will tell you what actions to take.

    Before or during the test, you may be given an iodine solution. This will keep your thyroid gland from absorbing too much iodine. Usually people take potassium iodide for 1 day prior and 6 days after. This blocks the thyroid from taking up the MIBG.

    This test should not be done on pregnant women. The radiation can pose danger to the unborn baby.

    Bleeker G, Tytgat GAM, Adam JA, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database Syst Rev. 2015;(9):CDC009263. PMID: 26417712 pubmed.ncbi.nlm.nih.gov/26417712/.

    Cohen DL, Fishbein L. Secondary hypertension: pheochromocytoma and paraganglioma. In: Bakris GL, Sorrentino MJ, eds. Hypertension: A Companion to Braunwald's Heart Disease. 3rd ed. Philadelphia, PA: Elsevier; 2018:chap 15.

    Oberg K. Neuroendocrine tumors and related disorders. In Melmed S, Auchus RJ, Goldfine AB, Koenig RJ, et al, eds. Williams Textbook of Endocrinology. 14th ed. Philadelphia, PA: Elsevier; 2020:chap 45.

    Yeh MW, Livhits MJ, Duh Q-Y. The adrenal glands. In: Townsend CM Jr, Beauchamp RD, Evers BM, Mattox KL, eds. Sabiston Textbook of Surgery. 21st ed. Philadelphia, PA: Elsevier; 2022:chap 40.

    Schedule An Appointment

    Contact Atlanta Obsetrics and Gynaecology at The Womens Center Millennium Hospital - 404-ATL-BABY

    GO

    Review Date: 7/5/2022

    Reviewed By: Jason Levy, MD, FSIR, Northside Radiology Associates, Atlanta, GA. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.